Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients |
| |
Authors: | E Marshall D B Smith S M O'Reilly A Murray V Kelly P I Clark |
| |
Institution: | (1) Department of Medical Oncology, Clatterbridge Centre for Oncology NHS Trust, Bebington, Wirral L63 4JY, UK e-mail: erniem@ccotrust.co.uk Tel.: +44-151-3344000 Fax: +44-151-4827675, GB;(2) Department of Microbiology, Clatterbridge Hospital, Wirral Hospitals NHS Trust Wirral L63 4JY, UK, GB;(3) Audit Department, Clatterbridge Centre for Oncology NHS Trust, Wirral L63 4JY, UK, GB |
| |
Abstract: | One hundred and thirty-five cancer patients admitted with low-risk neutropenic fever received a low-dose schedule of ceftazidime
as infusional monotherapy over a total of 180 episodes. Ceftazidime was administered as a 1-g bolus followed by a continuous
infusion of 2 g per day. In this patient population the ceftazidime was both practical and well tolerated. Sixty-eight percent
of patients responded with clinical improvement and complete resolution of fever within 48 h. Overall, 95% of patients responded,
although 18% subsequently required antibiotic modification for persistent fever. Only 5% of episodes were considered failures
due to clinical deterioration, and over the study period there was only 1 fatality due to respiratory failure. The median
duration of hospitalisation was only 4 days (2–20). In conclusion, monotherapy with low-dose infusional ceftazidime appears
safe and highly effective in this low-risk population of neutropenic patients and may reduce antibiotic costs appreciably.
Published online: 7 March 2000 |
| |
Keywords: | Neutropenic fever Ceftazidime Infusion |
本文献已被 SpringerLink 等数据库收录! |
|